RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 Safety and Tolerability Darexaban in Patients with ACS: The RUBY-1 Trial
JF MD Conference Express
YR 2011
FD SAGE Publications
VO 11
IS 10
SP 13
OP 14
DO 10.1177/155989771110005
UL http://mdc.sagepub.com/content/11/10/13.abstract
AB Results from the RUBY-I trial [NCT00994292] showed a dose-related, 2- to 4-fold increase in bleeding when the factor Xa inhibitor darexaban was added to standard treatment (aspirin with or without clopidogrel) for the secondary prevention of ischemic vascular events in patients with recent acute coronary syndrome.